A bitter melon compound slowed meningioma cells in lab tests
Original title: Integrated Transcriptomic and Functional Profiling Reveals IL-7R/FOXO1 Axis as a Target of Momordicine I in Meningioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on cells in a dish, not in people.
The short version
A natural compound from bitter melon killed meningioma tumor cells in a dish, but it has not been tested in people.
What was studied. Researchers grew human meningioma cells in the lab. They used two kinds of cells, one lab line called IOMM-Lee and one taken from a patient, called P9. Then they treated the cells with a compound from bitter melon called momordicine I.
What they found. The treated cells grew more slowly and formed fewer new colonies. They also moved less, and more of them died. Tests showed the cells had more DNA damage and made less of the proteins that help them survive. The way the cells made energy was also harmed.
What this means, and what it doesn't
What it could mean: This points to one possible new direction for treating meningioma, which has few drug options today. For now it is only a lead for more research. It does not change any care you can get.
What it doesn't mean: This does not mean bitter melon treats brain tumors. The work was done on cells in a dish, not in people or even in animals. Nobody knows yet if it is safe or if it works in a person. It is not a treatment, and it is not a cure. Any drug from this would take years of testing, and it may never work out. Do not take bitter melon or supplements based on this study. Talk to your doctor before changing anything.
Source: PubMed, August 10, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.